UPDATE 2-Biogen's MS drug misses main goal in mid-stage study

June 7 (Reuters) - Biogen Inc's keenly watched
experimental drug for treating multiple sclerosis failed to meet
the main goal of improving some symptoms in a mid-stage study,
sending the company's...